Benzenesulfonyl ureas and their use in treating diabetes

ABSTRACT

N-(4-(B-BENZAMIDO-ETHYL)-BENZENESULFONYL) -N&#39;&#39;(ENDOALKYLENECYCLOHEXYL- OR CYCLOHEXENYL)-UREAS BEING SUBSTITUTED AT THE BENZAMIDO GROUP AND HAVING HYPOGLYCEMIC ACTIVITY AND USEFUL FOR PREPARING PHARMACEUTICAL COMPOSITIONS AND USED IN A METHOD FOR LOWERING BLOOD SUGAR LEVEL IN THE TREATMENT OF DIABETES MELLITUS.

United States Patent F l Int. Cl. A61k 27/00 Us. Cl. 424-322 8 Claims a V 7 ABSTRACT OF THE DISCLOSURE 1 N-[ 4, (fl bcnzamido-ethyl) benzenesulfonyl] N- (endoalkylenecyclohexylor cyclohexenyl)-ureas being substituted at the 'benzamido group and having hypoglycemic activity and useful for preparing pharmaceutical compositions randtused in a method for lowering blood sugar level in the treatment of diabetes mellitus.

This is a divisionalapplication of Ser. No. 681,116, filed Nov. 7, 1967, now abandoned.

The present invention relates to benzenesulfonyl-ureas corresponding to the formula e v I 4 -o o-Nrroin -cr-u 1 OR p -SO2NHCONHR which as such or in the form of their physiologically tolerable salts show hypoglycemic properties and are characterized by a strong hypoglycemic action.

In the formula a R represents lower alkyl, preferably methyl or lower alkenyl,

X represents hydrogen, fluorine, chlorine or bromine, preferably chlorine, (lower alkyl, preferably methyl or lower alkoxy, preferably methoxy,

R represents endomethylene-cyclohexyl, endomethylenecyclohexenyl, endoethylene-cyclohexyl, endoethylenecyclohexenyl.

The substituent X is in 4- or preferably in 5-position to the carbonamidegroup. 1

In the above and the following definitions lower alkyl, alkenyl or alkoxy always stands for an alkyl, alkenyl or alkoxy group containing 1 to 4 carbon atoms in a straight or branched chain.

According to the above-mentioned definitions R may represent, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert.buty1, allyl.

In particular R may represent 2.5-endornethylenecyclohexenyl, 2.5-endomethyleuecyclohexyl, 2.5-end0- ethylenecyclohexyl, 2.5-endoethylenecyclohexenyl.

The present invention relates, furthermore to a process for the preparation of said benzenesulfonyl-ureas wherein (a) benzenesulfonyl-isocyanates, benzenesulfonyl carbamicacid esters, benzenesulfonyl-thiolcarbamic acid esters, benzenesulfonyl-carbamic acid halides or benzenesulfonyl-ureas, benzenesulfonyl-semicarbazides or benzenesulfonyl-semicarbazones substituted in p-position by the group 3,825,665 Patented July 23, 1974 or their salts are reacted with R -substituted isocyanates, carbamic acid esters, thiolcarbamic acid esters, carbamic acid halides or ureas,

(c) correspondingly substituted benzenesulfonyl-isourea ethers, benzene-sulfonyl-isourea esters, benzenesulfonylisothiourea ethers, benzenesulfonyl parabanic acids or benzenesulfonyl-haloformic acid amidines are hydrolyzed,

(d) correspondingly substituted benzenesulfonyl-halides are reacted with R -substituted ureas, in particular their alkaline metal salts,

(e) correspondingly substituted benzenesulfinic acid halides or, in the presence of acid condensing agents even correspondingly substituted benzenesulfinic acids or their alkaline metal salts, are reacted with hydroxy ureas the NH group of which being substituted by R (f) to correspondingly substituted carbodiimides water is added,

(g) in correspondingly substituted benzenesulfonyl-thicureas the sulfur atom is exchanged for an oxygen atom,

(h) correspondingly substituted benzenesulfinyl-ureas or benzenesulfenyl-ureas are oxidized,

(i) corresponding benzenesulfonyl-ureas containing in the molecule unsaturated linkages are hydrogenated,

(k) in benzenesulfonyl-ureas of the formula HzN-CHa-CHz-SOr-NH-CO-NH-R the radical is introduced by acylation, if desired in several stages, (I) in correspondingly substituted thiobenzamidoalkylbenzene-sulfonyl-ureas or -benzenesulfonyl-thioureas the sulfur atom or the sulfur atoms are exchanged by an oxygen atom or oxygen atoms, or (in) compounds of the formula or. their parabanic acid derivatives or compounds of the formula wherein U, represents O-lower alkyl, Slower alkyl or halogen (preferably chlorine) or saponified,

and the reaction products are treated with alkaline agents, if the formation of salts is desired.

The above-mentioned benzenesulfonyl-carbamic acid esters or the benzenesulfonyl-thiolcarbamic acid esters may contain in the alcohol component an alkyl radical or an aryl radical or a heterocyclic radical. Since this radical is split off during the reaction, its chemical constitution has no influence on the character of the final product and can therefore vary within wide limits. The same applies to the R -substituted carbamic acid esters or the corresponding thiolcarbamic acid esters.

As carbamic acid halides there are suitable, above all, the chlorides.

The benzenesulfonyl-ureas used as starting substances for the process of the invention may be unsubstituted at the side of the urea molecule opposite to the sulfonyl group or may be monoor preferably di-substituted. Since these substituents are split off during the reaction with amines, their nature can vary within wide limits. Instead of benzenesulfonyl-ureas substituted by an alkyl, aryl, acyl or heterocyclic radical, there can likewise be used the bis-(benzenesulfonyl)-ureas, which may carry a further substituent at one nitrogen atom, for example methyl. It is, for example, possible to treat such bis- (benzenesulfonyD-ureas or N-benzene-sulfonyl-N-acylureas with amines of the formula R NH and to heat the salts so obtained to an elevated temperature, particularly to a temperature above 100 C.

Furthermore, it is possible to start from ureas of the formula R NHCONH or from such ureas which are monoor, in particular di-substituted at the free nitrogen atom and to react these with benzenesulfonamides substituted by the grouping As such starting substances are appropriate, for example, N-endomethylenecyclohexyl, or Nendomethylenecyclohexenyl-urea, the corresponding N-acetylor N'-nitroureas, N endomethylenecyclohexyl-ureas, N'-endomethylenecyclohexenyl-ureas, N,N'-diphenyl-ureas (in which case the two phenyl radicals may be substituted and may be linked with one another directly or by means of a bridge member such as -CH --NH--, -O or -S,) N'-methyl-N'-phenylor N',N'-dicyclohexyl-ureas as well as R -substituted cyclohexyl carbamoyl-imidazoles or triazoles.

Hydrolysis of the mentioned benzenesulfonyl-parabanic acids, benzenesulfonyl-isourea-ethers, benzenesulfonylthio-urea-ethers, benzenesulfonyl-isourea-esters or benzene-sulfonyl-haloformic acid amidines is suitably carried out in an alkaline medium. Isourea-ethers and isoureaesters can be hydrolysed successfully in an acid medium, too.

The reaction with the benzenesulfonic halides with R1- substituted ureas is suitably carried out by using basic condensing agents such as alkali metals, alkali amides or, preferably, -hydrides in indifferent solvents.

The reaction of the sulfinic acids or sulfinic acid chlorides with hydroxy ureas can suitably be carried out in indifferent solvents. If the sulfinic acids or their alkali metals are used as starting substances, acid condensing agents such as for example thionyl chloride, polyphosphoric acids, anhydrous phosphoric acid or sulfuric acid are added.

The sulfur atom in correspondingly substituted benzenesulfonyl-thioureas can be replaced by an oxygen atom, in known manner, for example with the aid of oxides or salts of heavy metals or likewise by applying oxidizing agents such as hydrogen peroxide, sodium peroxide or nitrous acid.

Thioureas may also be desulfurized by treating them with phosgene or phosphorus pentachloride. Chloroformic acid amidines or carbodiimides obtained as intermediate products can 'be converted into the benzenesulfonyl-ureas by suitable processes such, for example, as saponification or addition of water.

The oxidation of the benzenesulfinylor -sulfenylureas can be carried out with the known oxidizing agents S ch as for example potassium permanganate in indifferent solvents.

correspondingly substituted benzenesulfonyl-ureas containing in the molecule an unsaturated bond, for example can be converted by hydrogenation for example with molecular hydrogen in the presence of a known hydration catalyst in the benzenesulfonyl-ureas according to the present invention.

The acylation of aminoethyl-benzenesulfonyl-ureas may be carried out either in one step, for example, by reaction of a correspondingly substituted benzoic acid halide, or it may be carried out in several steps. One example of the numerous possibilities of stepwise acylation is the reaction of amino-ethyl-benzenesulfonyl-ureas with Z-methoxy-benzoyl chloride and subsequent introduction of a halogen atom into the benzene nucleus of the benzamido group.

The sulfur atoms in correspondingly substituted thiobenzamido-ethyl-benzenesulfonyl-ureas or thiobenz-amidoethyl-benzenesulfonyl-thioureas can be replaced by oxygen atoms for example, With the air of oxidizing agents such as hydrogen peroxide, sodium peroxide or other peroxide compounds.

Instead of the thiobenzamido-ethyl-benzenesulfonylureas the corresponding thiobenzamidoethyl-benzenesulfonyl-isothio-urea-ethers, isourea-ethers or -esters, -para- 'banic acids or thiobenzamidoethyl-benzenesulfonyl-haloformic acid amidines can be desulfurized by treatment with oxidizing agents in an acid or alkaline medium whereby simultaneously a desulfurization and a hydrolysis forming the sulfonyl-urea grouping occur and the benzamidoethylbenzene-sulfonyl-ureas are obtained. A

Instead of the thiobenzamido-ethyl-benzene-sulfonylthioureas, compounds of the formula wherein U has the meaning given above, can be converted by treatment with oxidizing agents in an acid or alkaline medium by simultaneous desulfuration and hydrolysis into the corresponding benzamido-ethyl-benzenesulfonyl-ureas.

As regards the reaction conditions, the forms of realizing the process of the invention may, in general, vary within wide limits and can be adapted to each individual case. For example, the reactions can be carried out with the use of solvents either at room temperature or at an elevated temperature.

According to the nature of the starting substances, in some cases, one or the other mentioned process may yield a desired individual benzenesulfonyl-urea in only small amounts or might be inappropriate. Such relatively rare cases can easily be recognized by experts and it is not difiicult to use successfully a method of synthesis other than that described.

As starting substances such compounds are used which contain a benzene nucleus being substituted by the group R in para-position.

As examples for the part of this substituenti may; be mentioned in particular the following: l

H3O (CH3)2CH 1 dot-Ia (DCrHr H3? l I H3O (loin y l can donnm) H30 n30 r :l. w 0041-1901). ocHioH=cHi on3 rnc-Q ocnalon-co Qwm C2115 (kCII: CH3

U H3CO. C2H5O Q don-ndon, on,

"or-r3 on,

410031170 mo 0 a CO om CH3 Q- ()CzHs w OCzHa OCsHqfil) HaCO-CO mow-@wm 00- dcna 7 (ions dons F or 01 'oo- -oo- 430- I I I 00in, cm coin,

c1 01 Br -oo- -oo ool (T311701) 00411001) ()CIIg dons, 6CH(CH3)2 don,

a or can C4Hn(i) oonicmcn,

The preparation of the starting substances may be carried'out accordingto generally known methods, Thus, for example 'benzenesulfonarnides used as starting sub stances which are substituted in the benzene nucleus by the radical can be obtained by reaction of the corresponding benzene compounds with chloro-sulfonic acid and subsequently with ammonia or by acylation of amino compounds of the formula HZN-Cm-CHiQ-SOQNHZ with corresponding acid chlorides.

The benzenesulfonyl carbamic acid esters and -ureas used as starting material can be obtained for example from benzene-sulfonamides and halogenoformic acid alkyl esters or potassium cyanate (KOCN).

The hypoglycemic action of the benzene-sulfonyl-urea derivatives described above could be determined by feeding them to rabbits in doses of 10 mg./kg. and determining the blood sugar value according to the known method by Hagedorn-Jensen or by means of an autoanalyzer over a prolonged period of time.

Thus, it was found, for example, that 10 milligrams/ kilogram of N-[4({3- 2-methoxy-S-bromo-benzamido ethyl)-benzene sulfonyl] N (2.5-endomethylene-cyclohexyl)-urea provoke, after 3 hours, a lowering of the blood sugar by 35%, after 24 hours 26% and after 48 hours 18%.

In the same manner, 10 milligrams of -N-[4(,3- 2- methoxy 5 chlorobenzamido -ethyl)-benzene -sulfonyl]-N-(2.5 endomethylene cyclohexyl)-urea provoke after 3 hours a blood sugar lowering of 32%, after 24 hours of 43%, after 48 hours of 28%, and even after 72 hours of 14%, whereas the known N-[4-rnethyl-benzene-sulfonyl]-N-butyl-urea, when administered to rab bits in doses of less than 25 mg./kg., does not provoke a lowering of the blood sugar level.

The strong hypoglycemic action of the benzenesulfonyl-ureas of the present invention becomes more evident if the dose is further reduced. When N-[4-B- 2-methoxy 5 bromo-benzamido -ethyl)-benzenesulfony1]- N'-(2.S-endomethylene-cyclohexyl)urea is administered to rabbits in a dose of 0.01 mg./kg. or N-[4-(B- 2- methoxy 5 chloro benzamido -ethyl)-benzenesulfonyl]-N'-(2.5-endomethylene-cyclohexyl)-urea is admin istered to rabbits in a dose of 0.06 mg./kg., or the N-[4- (fl- 2-methoxy 5 methyl-benzamido -ethyl)-benzenesulfonyl1-N-(2.5-endomethylene-cyclohexyl)-urea is administered to rabbits in a dose of 0.06 mg./kg., a distinct lowering of the blood sugar can still be observed.

The benzensulfonyl-ureas described are preferably used for the manufacture of orally administrable pharmaceutical preparations for the lowering of the blood sugar level in the treatment of diabetes mellitus; they may be used as such or in the form of their physiologically tolerable salts or in the presence of substances which cause such salt formation. For the formation of salts there may be used, for example, alkaline agents such as alkali metal hydroxides or alkaline earth metal hydroxides, alkali metal carbonates or bicarbonates or alkaline earth metal carbonates or bicarbonates.

The pharmaceutical preparations are advantageously in the form of tablets containing, in addition to the products of the present invention, the usual pharmaceutically suitable carriers such as talc, starch, lactose, tragacanth or magnesium stearate.

A pharmaceutical preparation containing one of the aforesaid benzenesulfonyl-ureas as the active substance, for example, a tablet or a powder, with or without the aforesaid carriers, is advantageously brought into a suitable unit dosage form. The dose chosen should comply EXAMPLE 1 N-[4-(fi- 2-methoxy 5 chlorobenzamido -ethyl)-benzenesulfonyl] N (2.5 endomethylene-cyclohexyl) urea 4.2 g. of N-[4-(fl- 2-methoxy-5-chlorobenzamido ethyl)-benzenesulfonyl]-methyl-urethane (melting point 189191 C.) are suspended in 100 ml. of dioxane and heated for about 1 hour to 110 C. When cooling, the N-[4-(,8- 2-methoxy 5 chlorobenzamido -ethyl)-benzenesulfonyl]-N-(2.5 endomethylene cyclhexyl)-urea formed, crystallizes which, after recrystallization from methanol melts at 187l89 C.

In analogous manner there are obtained:

from N-[4-(fl- 2-methoxy 4 chlorobenzamido -ethyl)-benzenesulfonyl]-carbamic acid methyl ester (melting point 178-180 C.): N-[4-(fi- 2-methoxy-4-chlorobenzamido ethyl) benzenesulfonyl] N (2.5- endomethylenecyclohexyl)-urea, melting point 203- 205 C. (from methanol);

from N-[4-(;3- 2-eth0xy chlor0benzamido -ethyl)- benzenesulfonyl]-carbamic acid methyl ester (melting point 203205 C.): N-[4-(fl- 2-ethoxy-5-chlorobenzamido -ethyl)-benzenesulfonyl] N (2.5-endomethylenecyclohexyl)-urea, melting point 158l'60 C. (from methanol);

from N-[4-(,6- 2-methoxy 5 bromobenzamido -ethyl)-benzenesulfonyl]-carbamic acid methyl ester (melting point 197199 C.): N-[4-(,H- 2-methoxy-5-bromobenzamido -ethyl) benzenesulfonyl] N (2.5- endomethylenecyclohexyl)-urea, melting point 171 172 C. (from methanol/dimethylformamide);

from N-[4-(fl- 2-methoxy 5 methylbenzamido -ethyl)-benzenesulfonyl]-carbamic acid methyl ester (melting point 175-177 C.): N-[4-(,B- 2-methoxy-5-methylbenzamido ethyl) benzenesulfonyl] N (2.5- endomethylenecyclohexyl)-urea, melting point 191- 193 C. (from methanol/dimethylforrnamide);

from N-[4(fi- 2.5-dimethoxy benzamido -ethyl)-benzenesulfonyl1-carbamic acid methyl ester (melting point 173175 C.): N-[4-(,8- 2.5-dimethoxy-benzamido ethyl)-benzenesulfonyl] N (2.5-endomethylenecyclohexyl)-urea, melting point 163-165 C. (from methanol);

from N- [4- (fi- 2-methoxybenzamido -ethyl) -benzenesulfonyH-carbamic acid methyl ester (melting point 174176 C.) 2 N- [4-(B- 2-methoxybenzamido ethyl)-benzenesulfonyl]-N-(2.5-endomethylenecyclohexyl)-urea, melting point 197-198 C. (from methanol);

from N- [4- (,8- 2-methoxy-5-fiuorobenzamido -ethyl benzenesulfonyl]-carbamic acid methyl ester (melting point 171173 C.): N-[4-(B- 2-methoxy-5-fiuorobenzamido -ethyl -benzenesulfonyl] -N- 2.5 -endomethylenecyclohexyl)-urea, melting point 206-207 C. (from methanol/dimethylformamide).

EXAMPLE 2 N-[4-(fi- 2-methoxy 5 fluorobenzamido -ethyl)-benzenesulfonyl] N (2.5 endomethylenecyclohexyl)- urea is continued for 3 hours, water and methanol is added, the whole is filtered from the undissolved matter and the filtrate is acidified with dilute hydrochloric acid. The N- [4 (B- 2-methoxy-5-fiuorobenzamido -ethy1)-benzene sulfonyl] -N- 2.5-endomethylenecyclohexyl -urea which has precipitated, melts after recrystallization from methanol/dimethylformamide at' 206207 C.

In analogous manner there is obtained:

from 4- (,8- 2-n-propoxy-5-chlorobenzamido -ethyl)- benzenesulfonamide (melting point 192194 C.): N-[4-(/3- 2-n-propoxy-5-chlorobenzamido ethyl) -benzenesulfonyl] -N-(2.5-endomethylenecyclohexyl)-urea, melting point 17l173 C. (from methanol);

from 4- [3- 2-n-propoxy-5-methylbenzamido -ethyl) benzenesulfonamide (melting point 166-167 -C.): N- [4- fi- Z-n-propoxy-S-methylbenzamido ethyl)-benzenesulfonyl]-N'-(2.5-endomethylenecyclohexyl)-urea, melting point 148150 C. (from methanol);

from 4-(fl- 2-methoxy-5-ethylbenzamido -ethyl)-benzenesulfonamide (melting point 193195 C.): N-[4- fl- 2-methoxy-5-ethylbenzamido -ethyl) -benzenesulfonyl]-N-(2.5-endomethylenecyclohexyl)-urea, melting point 162164 C. (from methanol).

EXAMPLE 3 N-[4-(B- 2-methoxy 5 chloro benzamido -ethyl)- benzenesulfony1]-N'-(2.5 endomethylenecyclohexyl)- urea 2 g. of N-[4-(,8- 2-methoxy-5-chloro-benzamido ethyl)-benzenesulfonyl] N (2.5-endomethylenecyclohexyl)-thiourea (prepared by boiling for several hours 4 (fl- 2-methoxy-S-chloro-benzamido -ethyl)-benzenesulfonamide and 2.5-endomethylenecyclohexyl mustard oil in acetone in the presence of potassium carbonate while stirring, melting point 158160 C. (from dilute methano1)) are dissolved in about 10 ml. of 2N sodium hydroxide solution and 5 ml. of dioxane. After addition of 5 ml. of hydrogen peroxide of 35% strength, the whole is heated for about 20 minutes in a water bath. After cooling it is acidified. There is obtained a crystalline precipitate which is filtered oil with suction, dissolved in ammonia of about 1% strength and reprecipitated after filtration by acidification. The thus obtained crude N-[4- (fl- 2-methoxy 5 chlorobenzamido -ethyl)-benzenesulfonyl] -(2.S-endomethylenecyclohexyl -urea melts after recrystallization from methanol at 186188 C.

EXAMPLE 4 N [4 (,8 2-methoxy 5 chlorobenzamido -ethyl)- benzenesufonyl]-N'-(2.5 endomethylenecyclohexyl)- urea (a) 1 g. of N-[4-(,8- 2-methoxy-5-chlorobenzamido ethyl)-benzenesulfonyl] 1 (2.5-endomethylenecyclohexyl)-thiourea (cf. Example 3) is dissolved in 50 ml. of ethanol. After addition of 0.5 g. of mercury oxide and a small amount of potassium carbonate, the whole is heated to 5060 C. for 4 hours While stirring. It is filtered, concentrated and crystallized from dilute methanol. The thus obtained N-[4-(,8- 2-methoxy-5-chlorobenzamido -ethyl)-benzenesulfonyl] N (2.5-endomethylenecyclohexyl)-isourea methyl ether melts at 118-120 C.

(b) 0.1 g. of the product obtained according to 4(a), is heated in 2 ml. of dioxane and 10 ml. of concentrated hydrochloric acid for 20 minutes in a vapour bath. The product which is obtained after pouring into water is filtered off with suction and recrystallized from dilute methanol. The N-[4-(p- Z-methoxy-5-chloro-benzamido ethyl)-benzenesulfonyl] N (2.5-endomethylenecyclohexyl)-urea thus prepared melts at 1861'88 C. The same product is obtained by alkaline saponification of the isourea ether prepared according to 4(a) by heating for 1 N [4 (fi- 2-rnethoxy chlorobenzamido -ethyl)- benzenesulfonyl]-N-(2.5 endomethylenecyclohexyl)- urea (a) 0.8 g. of endomethylenecyclohexyhparabanic acid (melting point 1l1-113 C. from dilute methanol) is dissolved in 30 m1. of benzene, 0.4 g. of trimethylamine and 1.6 g. of 4-(/8- Z-methoxy-S-chlorobenzamido -ethyl)- benzenesulfonic acid chloride are added and heated to boil under reflux for 2 /2 hours. The whole is concentrated in vacuo, water is added to the residue obtained and it is triturated. The substance crystallizes after abandoning for some time. It is filtered off with suction, washed with water and recrystallized from methanol/dioxane. The thus obtained 1-[4-(, 2-methoxy-5-chlorobenzamido ethyl)-benzenesulfonyl] 3 (2.5-endomethylene-cycloheXyl)-parabanic acid melts at 227-229" C.

(b) The product obtained according to 5 (a) is dissolved in a small amount of dioxane and 2N sodium hydroxide solution and the solution is heated in a vapour bath for 45 minutes. After cooling it is diluted with water and acidified. The precipitate obtained of N-[4-(,3- 2-methoxy 5 chlorobenzamido -ethyl)-benzenesulfonyl1- N'-(2.5-endomethylenecyclohexyl)-urea melts after recrystallization from methanol/water at l86-188 C.

EXAMPLE 6 N- [4- fl- 2-methoxy-S-chlorobenzamido -ethyl) -benzenesulfonyl]-N- (2.5-endomethylenecyclohexyl) -urea (a) 3.1 g. of N-2.5-endomethylenecyclohexyl-urea are dissolved in pyridine, when introducing 7.4 g. of 4- (/3- 2- methoxy 5 chlorobenzamido -ethyl)-benzenesulfinyl chloride slight heating occurs. The clear solution is added after 10 minutes to a mixture of ice water and dilute hydrochloric acid, the precipitate thus formed is filtered oil with suction, and stirred with ammonia of 0.5% strength. The amorphous precipitate is dissolved in acetone while hot. When cooling, the N-[4- (pi- 2-methoxy-5-chlorobenzamido -ethyl)-benzenesulfinyl] N (2.5 endomethylenecyclohexyl)-urea crystallizes, having a melting point of 133135 C.

(b) 1 g. of the above-mentioned urea is dissolved in 20 ml. of dimethyl-formamide and an aqueous potassium permanganate solution in excess is added to the bath. After filtration of the pyrolusite, water and dilute hydrochloric acid is added and the precipitate which has formed is recrystallized. There is obtained N- [4-(,8- 2-methoxy-5- chlorobenzamido -ethyl) benzenesulfonyl] N (2.5- endomethylenecyclohexyl)-urea melting at 187189 C.

What we claim is:

1. A pharmaceutical composition which has hypoglycemic action and is suitable for oral administration in the treatment of diabetes mellitus, containing as the essential ingredient in an amount, effective to lower the blood sugar level, from 0.5 to 100 mg. per unit dosage, in addition to a pharmaceutical diluent, a benzene sulfonyl urea corresponding to the formula in which R represents lower alkyl or lower alkenyl;

X represents hydrogen, fluorine, chlorine, bromine, lower alkyl or lower alkoxy, in the 4- or S-position to the carbonamido group;

R represents endomethylene-cyclohexenyl, endomethylene-cyclohexyl, endoethylene-cyclohexyl or endoethylene-cyclohexenyl;

or a physiologically tolerable alkali or alkaline earth metal salt thereof.

2. The pharmaceutical composition according to Claim 1 wherein the benzene sulfonyl urea corresponds to the formula in which X represents fluorine, chlorine, bromine or methyl, and

R represents endomethylene-cyclohexenyl, endomethylene-cyclohexyl, endoethylene-cyclohexenyl or endoethylene-cyclohexyl, and wherein X is in the 4- or 5-position, or a physiologically tolerable alkali or alkaline earth metal salt thereof.

3. The pharmaceutical composition according to Claim 1 wherein R is methyl and R represents endomethylene cyclohexyl.

4. The pharmaceutical composition according to Claim 1 wherein R is methyl and R represents endomethylenecyclohexenyl.

5. The pharmaceutical composition according to Claim 1 wherein R is methyl and R represents endoethylenecyclohexyl.

6. The pharmaceutical composition according to Claim 1 wherein R is methyl and R is endoethylene-cyclohexenyl.

7. A method for lowering the blood sugar level in the treatment of diabetes mellitus, which comprises orally administering to a patient an effective amount, to lower blood sugar level, in a range from 0.5 to mg. per unit dosage of a benzenesulfonyl urea corresponding to the formula in which R represents lower alkyl or lower alkenyl;

X represents hydrogen, fluorine, chlorine, bromine, lower alkyl or lower alkoxy, in the 4- or S-position to the carbonamido group;

R represents endomethylene-cyclohexenyl, endomethylene-cyclohexyl, endoethylene-cyclohexyl or endoethylene-cyclohexenyl;

or a physiologically tolerable alkali or alkaline earth metal salt thereof.

The method for lowering blood sugar level as defined in Claim 7 wherein the benzene sulfonyl urea corresponds to the formula in which X represents fluorine, chlorine, bromine or methyl, and R represents endomethylene-cyclohexenyl, endomethylene-cyclohexyl, endoethylene-cyclohexenyl or endoethylene-cyclohexyl, and wherein X is in the 4- or S-position, or a physiologically tolerable alkali. or alkaline earth metal salt thereof.

References Cited UNITED STATES PATENTS 3,631,205 12/1971 Frey 424-422 VINCENT D. TURNER, Primary Examiner US. Cl. X.R. 260553 D I UNITED STATES PATENT. OFFitI E CERTIFICATE OF CORRECTION Patent No, 3,825,665 Dated July 23 1974 Inventor(g) Helmut Weber at 8.1.

It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

In the Heading; 7

After "Claims Priority, change "application" to --applicationsand after "F 50,793" insert I --and July 13, 1967 F 52,939.

Signed and sealed this 5th day of November 1974.

(SEAL) Attest:

MCQOY M. GIBSON JR. C. MARSHALL DANN Attesting' Officer Commissioner of Patents FORM PC4050 (10-69) USCOMM-DC U0376-P69 fr u.s. covsnuusnrramrms OFFICE n0 o-au-su, 

